Compare · DKDCA vs INCY
DKDCA vs INCY
Side-by-side comparison of Data Knights Acquisition Corp. (DKDCA) and Incyte Corp. (INCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DKDCA and INCY operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- INCY is the larger of the two at $24.01B, about 159.1x DKDCA ($150.9M).
- INCY has hit the wire 26 times in the past 4 weeks while DKDCA has been quiet.
- INCY has more recent analyst coverage (25 ratings vs 0 for DKDCA).
- Company
- Data Knights Acquisition Corp.
- Incyte Corp.
- Price
- $7.02+17.00%
- $120.62+1.85%
- Market cap
- $150.9M
- $24.01B
- 1M return
- -
- +4.32%
- 1Y return
- -
- +54.54%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 26
- Recent ratings
- 0
- 25
Incyte Corp.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Latest DKDCA
- SEC Form SC 13G/A filed by Data Knights Acquisition Corp. (Amendment)
- Data Knights Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form SC 13G/A filed by Data Knights Acquisition Corp. (Amendment)
- SEC Form S-1 filed by Data Knights Acquisition Corp.
- Data Knights Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Data Knights Acquisition Corp.
- New insider Casey Paul claimed ownership of 599,172 shares (SEC Form 3)
- New insider Kosasa Thomas claimed ownership of 4,952,409 shares (SEC Form 3)
- SEC Form NT 10-Q filed by Data Knights Acquisition Corp.
- Data Knights Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status
Latest INCY
- President, Global Head of R&D Cagnoni Pablo J sold $1,901,794 worth of shares (15,888 units at $119.70), decreasing direct ownership by 7% to 215,444 units (SEC Form 4)
- EVP & Chief Scientific Officer Mayes Patrick A exercised 45,767 shares at a strike of $78.48 and sold $5,734,376 worth of shares (47,954 units at $119.58), decreasing direct ownership by 3% to 61,441 units (SEC Form 4)
- New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
- Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
- SEC Form 10-Q filed by Incyte Corp.
- Incyte Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
- SEC Form 4 filed by EVP, Head of Tech. Operations Morrissey Michael James
- SEC Form 4 filed by EVP, Head of Incyte Intl Heeson Lee
- Principal Accounting Officer Tray Thomas was granted 2,834 shares, increasing direct ownership by 15% to 21,699 units (SEC Form 4)